Modality
Multispecific
MOA
RAS(ON)i
Target
ALK
Pathway
Lipid Met
PsA
Development Pipeline
Preclinical
~Nov 2013
→ ~Feb 2015
Phase 1
~May 2015
→ ~Aug 2016
Phase 2
~Nov 2016
→ ~Feb 2018
Phase 3
~May 2018
→ ~Aug 2019
NDA/BLA
~Nov 2019
→ ~Feb 2021
Approved
May 2021
→ Jan 2030
ApprovedCurrent
NCT06920480
2,046 pts·PsA
2021-05→2030-01·Not yet recruiting
NCT07645982
1,132 pts·PsA
2021-11→2027-10·Active
3,178 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2027-10-011.5y awayPh3 Readout· PsA
2030-01-283.8y awayPh3 Readout· PsA
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2027-10-01 · 1.5y away
PsA
Ph3 Readout
2030-01-28 · 3.8y away
PsA
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06920480 | Approved | PsA | Not yet recr... | 2046 | EDSS |
| NCT07645982 | Approved | PsA | Active | 1132 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |